Ovid Therapeutics Inc.
OVIDHealthcareNASDAQBiotechnology
Scan Results
Daily timeframePart of the healthcare sector, Ovid Therapeutics Inc. (OVID) is listed under Biotechnology. The company carries a $455.4M market cap, placing it firmly in the small-cap category. The company is developing OV329, a GABA-AT inhibitor which is in Phase 1 clinical trials for the treatment of adult and infant drug-resistant epilepsies; and OV4071, a first-in-human oral potassium-chloride cotransporter 2 direct activator which is in Phase 1 clinical trials for the treatment of psychosis associated with parkinson's disease, lewy body dementia, and acute schizophrenia.
Market Cap
$455.4M
Beta
0.19
P/E (TTM)
—
P/E (Fwd)
-5.40
EPS (TTM)
$-0.21
EPS (Fwd)
$-0.45
ROE
-18.8%
ROA
-19.7%
Cash
$155.5M
Total Debt
$13.1M
Free CF
-$20.8M
52W Change
343.6%
Annual Financials
Cash vs Debt
With $155.5M in cash and $13.1M in debt, OVID maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. Free cash flow is running at -$20.8M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. ROE of -18.8% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has grown from $1.5M (2022) to $7.3M (2025), reflecting a 383% increase over the period.
The relatively low beta of 0.19 suggests OVID is a less volatile holding compared to the broader index. The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing OVID.